HAVN Life Sciences Inc.
HAVLF · OTC
4/30/2022 | 4/30/2021 | 4/30/2020 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $5 | $0 |
| Gross Profit | $0 | -$5 | $0 |
| % Margin | 32.4% | – | – |
| R&D Expenses | $1 | $0 | $0 |
| G&A Expenses | $8 | $19 | $0 |
| SG&A Expenses | $9 | $19 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $5 | $0 |
| Operating Expenses | $10 | $24 | $0 |
| Operating Income | -$10 | -$30 | -$0 |
| % Margin | -3,548.4% | – | – |
| Other Income/Exp. Net | -$13 | -$0 | $0 |
| Pre-Tax Income | -$22 | -$30 | -$0 |
| Tax Expense | $0 | $0 | -$0 |
| Net Income | -$22 | -$30 | -$0 |
| % Margin | -8,117.8% | – | – |
| EPS | -5.25 | -8.47 | -0.018 |
| % Growth | 38% | -46,438.5% | – |
| EPS Diluted | -5.25 | -8.47 | -0.018 |
| Weighted Avg Shares Out | 4 | 4 | 2 |
| Weighted Avg Shares Out Dil | 4 | 4 | 2 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $5 | $0 |
| EBITDA | -$7 | -$15 | $0 |
| % Margin | -2,711.4% | – | – |